Scinovex
review Open AccessTop 1% cited

Lipase Inhibitors for Obesity: A Review

Biomedicine & Pharmacotherapy · 2020 · Vol. 128 · pp. 110314–110314
Tiantian LiuXiaotian LiuQing‐Xi ChenYan Shi

Abstract

With the rapid increase in the population of obese individuals, obesity has become a global problem. Many kinds of chronic metabolic diseases easily caused by obesity have received increasing attention from researchers. People are also striving to find various safe and effective treatment methods as well as anti-obesity medicines. Pancreatic lipase (PL) inhibitors have received substantial attention from researchers in recent years, and PL inhibitors from natural products have attracted much attention due to their structural diversity, low toxicity and wide range of sources. They have been used in the intestinal tract, blood, and the central nervous system with no side effects, and these advantages could lead to a new generation of diet pills or health care products with great development potential. This article is mainly aimed at discussing the research of obesity drug treatment with PL inhibitors and offers a brief review of related properties and the use of PL inhibitors in the field of weight loss.

Pharmacology and Obesity TreatmentNatural Antidiabetic Agents StudiesMetabolism, Diabetes, and CancerObesityMedicinePillPharmacologyBioinformaticsBiologyInternal medicine

MeSH terms

AnimalsEnzyme InhibitorsHumansLipaseObesityWeight LossAnti-Obesity AgentsAdiposityLipid Metabolism

Funding

  • National Natural Science Foundation of China
Citations
390
FWCI
33.47
field-weighted impact
References
94
Percentile
100%
vs. same field & year
Citations per year
References
Lowering blood cholesterol to prevent heart disease
Journal of Oral and Maxillofacial Surgery · 1985 · 655 citations
Nonalcoholic Fatty Liver Disease
Diabetes · 2001 · 2,575 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Lipase Inhibitors for Obesity: A Review · Scinovex